Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000170873 | SCV000223428 | uncertain significance | not provided | 2023-05-25 | criteria provided, single submitter | clinical testing | Has not been previously published as pathogenic or benign to our knowledge; In silico analysis supports that this missense variant does not alter protein structure/function; Variants in candidate genes are classified as variants of uncertain significance in accordance with ACMG guidelines (Richards et al., 2015); This variant is associated with the following publications: (PMID: 31589614) |
Invitae | RCV000810801 | SCV000951035 | uncertain significance | Brugada syndrome 4 | 2021-09-02 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine with serine at codon 494 of the CACNB2 protein (p.Gly494Ser). The glycine residue is highly conserved and there is a small physicochemical difference between glycine and serine. This variant is present in population databases (rs730880059, ExAC 0.009%). This variant has not been reported in the literature in individuals affected with CACNB2-related conditions. ClinVar contains an entry for this variant (Variation ID: 180290). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV002390371 | SCV002702541 | uncertain significance | Cardiovascular phenotype | 2023-09-06 | criteria provided, single submitter | clinical testing | The p.G494S variant (also known as c.1480G>A), located in coding exon 13 of the CACNB2 gene, results from a G to A substitution at nucleotide position 1480. The glycine at codon 494 is replaced by serine, an amino acid with similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV000810801 | SCV002817007 | uncertain significance | Brugada syndrome 4 | 2022-02-09 | criteria provided, single submitter | clinical testing | |
Blueprint Genetics | RCV000157131 | SCV000206854 | uncertain significance | Cardiac arrest | 2014-09-18 | no assertion criteria provided | clinical testing |